Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI322 Safety and Efficacy in Advanced Solid Tumors
NCT04912466Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simridarlimab in solid tumor (advanced stage), sponsored by Innovent Biologics. Primary endpoints: Number of Dose Limiting Toxicities at 21 Days, Number of treatment related Adverse Events and 1 more. Started Jul 2021; status: completed.
02
Drugs
simridarlimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04912466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912466.